SPIRIVA® RESPIMAT® (tiotropium bromide) Inhalation Spray Now Available in the United States for the Maintenance Treatment of COPD
RIDGEFIELD, CONN. -January 21, 2014- Boehringer Ingelheim Pharmaceuticals, Inc. announced today that SPIRIVA® RESPIMAT® (tiotropium bromide) Inhalation Spray is now available by prescription through retail pharmacies across the United States.
Recently, SPIRIVA® RESPIMAT® was approved by the U.S. Food and Drug Administration (FDA), and was developed to deliver medication via a slow-moving mist that helps patients inhale the medication.
“For 10 years, SPIRIVA HandiHaler has been a trusted maintenance therapy for patients with COPD, and Boehringer Ingelheim is proud to now offer another inhaler choice, SPIRIVA RESPIMAT,” said Danny McBryan, MD, vice president, Clinical Development & Medical Affairs, Respiratory, Boehringer Ingelheim Pharmaceuticals, Inc. “SPIRIVA RESPIMAT represents Boehringer Ingelheim’s continuing commitment to the COPD community to provide new treatment options.”
Read the full release here.